Recombinant Human Kallikrein 6/KLK6 Protein (His Tag)(Active) | PKSH030894

Recombinant Human Kallikrein 6/KLK6 Protein (His Tag)(Active) | PKSH030894 | Gentaur US, UK & Europe Disrtribition

Synonyms: Kallikrein-6; Neurosin; Protease M; SP59; Serine Protease 18; Serine Protease 9; Zyme; KLK6; PRSS18; PRSS9

Active Protein: Active protein

Activity: A DNA sequence encoding the human KLK6 isoform 1 (Q92876-1) (Met 1-Lys 244), was fused with a polyhistidine tag at the C-terminus.

Protein Construction: A DNA sequence encoding the human KLK6 isoform 1 (Q92876-1) (Met 1-Lys 244), was fused with a polyhistidine tag at the C-terminus.

Fusion Tag: C-His

Species: Human

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 26.6 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: KLK6 (kallikrein-related peptidase 6), also known as Klk7, belongs to the peptidase S1 family, Kallikrein subfamily. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK6 is a serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Klk7 shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. KLK6 degrades alpha-synuclein and prevents its polymerization, indicating that KLK6 may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. Klk7 may be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis.

Research Area: N/A